Transparency sounds like a good thing. And in many cases, it is. But in healthcare policy, I’ve seen a troubling pattern: Transparency gets weaponized. Not to inform decisions. Not to improve outcomes. But to delay progress, justify inaction, or create political cover.

There’s a myth in leadership that experience automatically makes you better. But I’ve learned, on the racetrack, in health policy, and in research funding, that experience without adaptability is just a heavier anchor. The world changes. Fast. And if you’re clinging to “what used to work,” you’re not leading. You’re coasting.

That’s what happened with a recent study the JKTG Foundation supported, one that explored how iron-based nanoparticles could help detect and treat tumors more safely. This wasn’t hype. It was smart, specific science. And it’s the kind of work we’re proud to back.

You don’t usually associate spreadsheets with survival rates. But that’s exactly the connection Dr. Paul Macklin is exploring in our latest Driving Research episode.

For decades, we’ve known Medicare’s financial challenges were coming. The math hasn’t changed. The program continues to spend more than it brings in, and the demographic reality is unavoidable: more retirees, fewer workers, and escalating healthcare costs.

There’s a common trap leaders fall into: They assume because they’ve seen something before, they know exactly how to handle it now. I’ve seen this play out in racing. I’ve seen it in healthcare policy meetings. I’ve seen it in boardrooms. And I’ve learned that past experience can mislead you if you treat it like gospel.

You get results: faster, sharper, and more aligned with what patients truly need. That was the driving force behind the 9th annual JKTG Symposium, held October 15, 2025 in Washington D.C. This year’s theme, "Improving Breast Cancer Outcomes: Revealing and Targeting Tumor–Immune Interactions," was more than a title. It was a call to action.

This weekend marked the final race of our season: Road Atlanta. And I’ll be honest… We knew all we had to do was start the race to win the Bronze Cup Championship. But that’s never been how we operate. We came to compete.

If you want to slow progress down, wrap it in red tape. That’s the reality for far too much medical research in this country. Scientists with bold ideas spend more time formatting grant proposals than actually running experiments. And when the funding does come through, it’s often a year too late, tied up in approval cycles, institutional requirements, and layers of administrative overhead. The worst part? Some of the most promising ideas never even get submitted. They’re too